Search details
1.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-34784056
2.
Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting.
Future Oncol
; 18(3): 301-309, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34709061
3.
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
J Urol
; 205(2): 554-560, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33090917
4.
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
J Urol
; 203(4): 743-750, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-31580749
5.
Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.
Curr Oncol
; 31(1): 501-510, 2024 01 14.
Article
in English
| MEDLINE | ID: mdl-38248119
6.
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.
JCO Oncol Pract
; 20(1): 145-153, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37556776
7.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
J Immunother Cancer
; 10(2)2022 02.
Article
in English
| MEDLINE | ID: mdl-35210307
8.
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
BMJ Open
; 12(9): e058396, 2022 09 14.
Article
in English
| MEDLINE | ID: mdl-36104138
9.
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Support Care Cancer
; 19(10): 1609-17, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-20835873
10.
Impact of the COVID-19 pandemic on specialty community practices: an oncology perspective.
Am J Manag Care
; 26(10 Spec No.): SP333-SP335, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33395241
11.
Recent study on site of care has severe limitations.
Am J Manag Care
; 24(10): 450, 2018 10.
Article
in English
| MEDLINE | ID: mdl-30325184
12.
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.
J Clin Oncol
; 23(6): 1096-102, 2005 Feb 20.
Article
in English
| MEDLINE | ID: mdl-15657402
13.
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
Curr Med Res Opin
; 22(7): 1403-13, 2006 Jul.
Article
in English
| MEDLINE | ID: mdl-16834839
14.
Use of Adjuvant Chemotherapy After Surgery in Patients With Colon Cancer.
JAMA Surg
; 152(9): 894-895, 2017 09 01.
Article
in English
| MEDLINE | ID: mdl-28614549
Results
1 -
14
de 14
1
Next >
>>